


## AR453588 hydrochloride

Cat. No.:	HY-133127A
CAS No.:	1065606-97-4
Molecular Formula:	C <sub>25</sub> H <sub>26</sub> ClN <sub>7</sub> O <sub>2</sub> S <sub>2</sub>
Molecular Weight:	556.1
Target:	Glucokinase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC <sub>50</sub> of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity <sup>[1]</sup> .																
<b>In Vivo</b>	<p>AR453588 hydrochloride (3-30 mg/kg; p.o) lowers post-prandial glucose in normal C57BL/6J mice<sup>[1]</sup>.</p> <p>AR453588 hydrochloride (3-30 mg/kg; p.o.; once-daily for 14 days) shows anti-hyperglycemic activity in a dose-ranging 14 day ob/ob mouse<sup>[1]</sup>.</p> <p>AR453588 hydrochloride (10 mg/kg; p.o.) treatment shows that the T<sub>max</sub>, AUC<sub>inf</sub>, V<sub>ss</sub>, C<sub>max</sub> and F are 1.0 mL/min/kg, 4.65 h μg/mL, 1.67 μg/mL and 60.3%, respectively<sup>[1]</sup>.</p> <p>AR453588 hydrochloride (1 mg/kg; i.v.) treatment shows that the CL, AUC<sub>inf</sub>, V<sub>ss</sub>, and t<sub>1/2</sub> are 21.6 mL/min/kg, 0.77 h μg/mL, 0.746 L/kg and 1.28 hours, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male diabetic ob/ob mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>3, 10, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally once-daily for 14 days</td> </tr> <tr> <td>Result:</td> <td>Lowered the fasted blood glucose from the control animals on day 14 as well as the AUC of the OGTT (oral glucose tolerance tests).</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male CD-1 mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o. (Pharmacokinetic Analysis)</td> </tr> <tr> <td>Result:</td> <td>The T<sub>max</sub>, AUC<sub>inf</sub>, V<sub>ss</sub>, C<sub>max</sub> and F were 1.0 mL/min/kg, 4.65 h μg/mL, 1.67 μg/mL and 60.3%, respectively</td> </tr> </table>	Animal Model:	Male diabetic ob/ob mice <sup>[1]</sup>	Dosage:	3, 10, 30 mg/kg	Administration:	Orally once-daily for 14 days	Result:	Lowered the fasted blood glucose from the control animals on day 14 as well as the AUC of the OGTT (oral glucose tolerance tests).	Animal Model:	Male CD-1 mice <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	p.o. (Pharmacokinetic Analysis)	Result:	The T <sub>max</sub> , AUC <sub>inf</sub> , V <sub>ss</sub> , C <sub>max</sub> and F were 1.0 mL/min/kg, 4.65 h μg/mL, 1.67 μg/mL and 60.3%, respectively
Animal Model:	Male diabetic ob/ob mice <sup>[1]</sup>																
Dosage:	3, 10, 30 mg/kg																
Administration:	Orally once-daily for 14 days																
Result:	Lowered the fasted blood glucose from the control animals on day 14 as well as the AUC of the OGTT (oral glucose tolerance tests).																
Animal Model:	Male CD-1 mice <sup>[1]</sup>																
Dosage:	10 mg/kg																
Administration:	p.o. (Pharmacokinetic Analysis)																
Result:	The T <sub>max</sub> , AUC <sub>inf</sub> , V <sub>ss</sub> , C <sub>max</sub> and F were 1.0 mL/min/kg, 4.65 h μg/mL, 1.67 μg/mL and 60.3%, respectively																

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA